Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myelomonocytic, Juvenile 1Down Syndrome 1Burkitt Lymphoma 1

Interventions

Specimen Handling 481pembrolizumab 454Magnetic Resonance Spectroscopy 419Carboplatin 321Cyclophosphamide 314Biopsy 272Cisplatin 264Radiotherapy 239Paclitaxel 226Gemcitabine 222Bevacizumab 212Nivolumab 189fludarabine 183venetoclax 172Drug Therapy 165Dexamethasone 157Blood Specimen Collection 156Oxaliplatin 154Injections 152Capecitabine 152Fluorouracil 144Docetaxel 142Standard of Care 136Radiosurgery 136Rituximab 125Pemetrexed 115durvalumab 113atezolizumab 110Leucovorin 110Radiation 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × hydrocortisone hemisuccinate × 1 year × Clear all
NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Oncology Group

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡